全文获取类型
收费全文 | 51298篇 |
免费 | 5444篇 |
国内免费 | 676篇 |
专业分类
耳鼻咽喉 | 464篇 |
儿科学 | 2194篇 |
妇产科学 | 1017篇 |
基础医学 | 6255篇 |
口腔科学 | 1499篇 |
临床医学 | 9083篇 |
内科学 | 4697篇 |
皮肤病学 | 311篇 |
神经病学 | 5539篇 |
特种医学 | 891篇 |
外国民族医学 | 4篇 |
外科学 | 3632篇 |
综合类 | 4917篇 |
现状与发展 | 6篇 |
一般理论 | 12篇 |
预防医学 | 9374篇 |
眼科学 | 594篇 |
药学 | 3769篇 |
47篇 | |
中国医学 | 1447篇 |
肿瘤学 | 1666篇 |
出版年
2024年 | 475篇 |
2023年 | 1133篇 |
2022年 | 1457篇 |
2021年 | 2215篇 |
2020年 | 2421篇 |
2019年 | 2403篇 |
2018年 | 2141篇 |
2017年 | 2186篇 |
2016年 | 2053篇 |
2015年 | 2092篇 |
2014年 | 3061篇 |
2013年 | 3983篇 |
2012年 | 2747篇 |
2011年 | 2892篇 |
2010年 | 2588篇 |
2009年 | 2504篇 |
2008年 | 2406篇 |
2007年 | 2389篇 |
2006年 | 2046篇 |
2005年 | 1808篇 |
2004年 | 1529篇 |
2003年 | 1327篇 |
2002年 | 1098篇 |
2001年 | 940篇 |
2000年 | 828篇 |
1999年 | 752篇 |
1998年 | 696篇 |
1997年 | 566篇 |
1996年 | 514篇 |
1995年 | 482篇 |
1994年 | 425篇 |
1993年 | 360篇 |
1992年 | 326篇 |
1991年 | 268篇 |
1990年 | 265篇 |
1989年 | 197篇 |
1988年 | 193篇 |
1987年 | 170篇 |
1986年 | 187篇 |
1985年 | 221篇 |
1984年 | 209篇 |
1983年 | 124篇 |
1982年 | 112篇 |
1981年 | 136篇 |
1980年 | 126篇 |
1979年 | 78篇 |
1978年 | 76篇 |
1977年 | 40篇 |
1976年 | 47篇 |
1974年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
目的了解感染铜绿假单胞菌老年患者的耐药性特征,为临床预防及治疗提供理论依据。方法收集我院2013年1月至2014年7月感染铜绿假单胞菌的老年患者病例233例,采用Kirby-Bauer纸片扩散法和CLSI 2013年版判断标准进行耐药性监测,并用SPSS 19.0统计软件进行数据分析。结果阿米卡星耐药率最低,其他耐药率低于60%的包括庆大霉素、妥布霉素、复方新诺明、罗米沙星、左氧氟沙星、环丙沙星、美罗培南、亚胺培南、头孢吡肟、哌拉西林、哌拉西林/他唑巴坦、头孢他啶。结论老年患者中分离的铜绿假单胞菌呈现出多重耐药且耐药率不断上升的特点,建议根据药敏结果选择抗菌药物并联合用药。 相似文献
993.
In 2005, the European Respiratory Society (ERS) launched a project to harmonise education and training and to address the heterogeneity of respiratory health training across Europe. Since then, various educational activities have been developed for different target audiences. This article will describe the overall methodology and the projects developed over the years, detailing their objectives and target audiences. Moving forward, ERS strives to provide a structure for the continuing professional development of respiratory physicians. 相似文献
994.
Carine Beysen DPhil Patricia Schroeder PhD Eric Wu PhD Julie Brevard MPH Maria Ribadeneira PhD Wei Lu PhD Kiran Dole PharmD Terry O'Reilly MD Linda Morrow MD Marcus Hompesch MD Marc K. Hellerstein MD Kelvin Li PhD Lars Johansson PhD Patrick F. Kelly MD 《Diabetes, obesity & metabolism》2021,23(3):700-710
995.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2022,16(3):102437
Background and aimsThis study aimed to assess the effects of vildagliptin on the prevention of cardiovascular diseases in Thai patients with type 2 diabetes mellitus using the Thai Cardiovascular Risk Score.MethodsAll patients with type 2 diabetes mellitus who used vildagliptin at a secondary hospital in Thailand were screened and recruited. The relevant variables were obtained from patient medication charts at the first visit on which the patients were prescribed vildagliptin and from the 6-month, 12-month, and 18-month post-treatment visits. The Thai Cardiovascular Risk Score was calculated and monitored as a primary outcome, whereas changes in separate cardiometabolic parameters were assessed as secondary outcomes.ResultsOf the 321 patients screened, only 95 were recruited for the analysis. The average 10-year cardiovascular risks of patients increased from 19.65% at baseline to 20.74%, 20.69%, and 23.78% at 6, 12, and 18 months post treatment, respectively. However, a better trend of reduction in cardiovascular risk was observed in patients with a high baseline cardiovascular risk. The glucose-lowering effects of vildagliptin were significantly observed 12 months of treatment onwards, but non-significant changes were found in lipid and blood pressure levels as well as body mass index.ConclusionVildagliptin provided a promising glucose-lowering effect in Thai patients with type 2 diabetes mellitus. However, the mean 10-year cardiovascular risk did not significantly decrease. However, a negative correlation between cardiovascular risk reduction and baseline cardiovascular risk was observed in this study. Low sample size was a major limitation of this study. 相似文献
996.
997.
998.
999.
1000.
George Demiris Sarah J. Iribarren Katherine Sward Solim Lee Rumei Yang 《Nursing outlook》2019,67(4):311-330
BackgroundPrecision health calls for collecting and analyzing large amounts of data to capture an individual's unique behavior, lifestyle, genetics, and environmental context. The diffusion of digital tools has led to a significant growth of patient generated health data (PGHD), defined as health-related data created, gathered or inferred by or from patients and for which the patient controls data collection and data sharing.PurposeWe assessed the current evidence of the impact of PGHD use in clinical practice and provide recommendations for the formal integration of PGHD in clinical care.MethodsWe searched PubMed, Ovid, Embase, CINAHL, Web of Science, and Scopus up to May 2018. Inclusion criteria were applied and four reviewers screened titles and abstracts and consequently full articles.FindingsOur systematic literature review identified 21 studies that examined the use of PGHD in clinical settings. Integration of PGHD into electronic records was extremely limited, and decision support capabilities were for the most part basic.DiscussionPGHD and other types of patient-reported data will be part of the health care system narrative and we must continue efforts to understand its impact on health outcomes, costs, and patient satisfaction. Nursing scientists need to lead the process of defining the role of PGHD in the era of precision health. 相似文献